West Pharmaceutical Services, Inc. (NYSE:WST) to Post Q1 2023 Earnings of $1.81 Per Share, Jefferies Financial Group Forecasts

West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) – Analysts at Jefferies Financial Group issued their Q1 2023 earnings estimates for shares of West Pharmaceutical Services in a research note issued to investors on Tuesday, January 24th. Jefferies Financial Group analyst D. Windley forecasts that the medical instruments supplier will post earnings of $1.81 per share for the quarter. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $8.18 per share. Jefferies Financial Group also issued estimates for West Pharmaceutical Services’ Q2 2023 earnings at $2.01 EPS, Q4 2023 earnings at $2.00 EPS, Q1 2024 earnings at $2.05 EPS and FY2024 earnings at $8.92 EPS.

West Pharmaceutical Services (NYSE:WSTGet Rating) last released its quarterly earnings results on Thursday, October 27th. The medical instruments supplier reported $2.03 EPS for the quarter, missing analysts’ consensus estimates of $2.12 by ($0.09). The firm had revenue of $686.90 million for the quarter, compared to analysts’ expectations of $730.64 million. West Pharmaceutical Services had a return on equity of 28.15% and a net margin of 21.68%.

WST has been the subject of several other reports. Bank of America cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $385.00 to $250.00 in a research report on Friday, October 28th. KeyCorp reduced their price target on shares of West Pharmaceutical Services from $350.00 to $315.00 and set an “overweight” rating for the company in a report on Friday, December 2nd. Deutsche Bank Aktiengesellschaft began coverage on shares of West Pharmaceutical Services in a report on Tuesday, December 13th. They issued a “hold” rating and a $250.00 price target for the company. UBS Group assumed coverage on shares of West Pharmaceutical Services in a report on Wednesday, November 30th. They issued a “neutral” rating and a $250.00 price target for the company. Finally, StockNews.com assumed coverage on shares of West Pharmaceutical Services in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $266.25.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $258.33 on Wednesday. The stock has a market cap of $19.12 billion, a price-to-earnings ratio of 31.16, a price-to-earnings-growth ratio of 2.44 and a beta of 1.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.80 and a quick ratio of 2.89. West Pharmaceutical Services has a 1 year low of $206.19 and a 1 year high of $424.00. The firm has a 50-day moving average of $238.50 and a two-hundred day moving average of $266.35.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 1st. Shareholders of record on Wednesday, January 25th will be paid a dividend of $0.19 per share. The ex-dividend date is Tuesday, January 24th. This represents a $0.76 dividend on an annualized basis and a yield of 0.29%. West Pharmaceutical Services’s payout ratio is 9.17%.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 44,000 shares of the company’s stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $238.99, for a total transaction of $10,515,560.00. Following the transaction, the chief executive officer now owns 114,922 shares in the company, valued at approximately $27,465,208.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of WST. CX Institutional purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at $28,000. Janiczek Wealth Management LLC boosted its holdings in West Pharmaceutical Services by 103.6% during the fourth quarter. Janiczek Wealth Management LLC now owns 112 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 57 shares in the last quarter. Guardian Wealth Advisors LLC purchased a new stake in West Pharmaceutical Services during the third quarter worth $29,000. Householder Group Estate & Retirement Specialist LLC purchased a new stake in West Pharmaceutical Services during the third quarter worth $36,000. Finally, Allworth Financial LP boosted its holdings in West Pharmaceutical Services by 70.8% during the second quarter. Allworth Financial LP now owns 123 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 51 shares in the last quarter. Institutional investors and hedge funds own 91.51% of the company’s stock.

About West Pharmaceutical Services

(Get Rating)

West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.

Featured Articles

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.